GlassScriptPhysician profile
Javier I Torrens
NPI 1578555298
$102,703.25
in general payments reported to CMS, 2019-2025
37 companies · $975 in 2025
The $975 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $25K · 2021: $20K · 2022: $20K · 2023: $532 · 2024: $1,089 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $58,320.12 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,414.04 | 2019-2024 | Synjardy, Jardiance |
| Astrazeneca Pharmaceuticals LP | $12,371.18 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $9,626.24 | 2019-2020 | |
| Lilly USA, LLC | $6,390.43 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $431.63 | 2019-2025 | Evenity, Tepezza, Prolia |
| Dexcom, INC. | $279.84 | 2019-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $228.51 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $180.51 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Janssen Pharmaceuticals, INC | $164.75 | 2019-2020 | |
| Medtronic, INC. | $152.82 | 2023-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $147.11 | 2019-2025 | |
| Abbvie INC. | $144.43 | 2019-2025 | |
| Abbott Laboratories | $140.07 | 2023-2025 | Freestyle Libre, Eterna |
| Ibsa Pharma INC. | $90.25 | 2023-2025 | Tirosint, Tirosint, Licart |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $64.89 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $64.09 | 2023-2024 | Cequr Simplicity |
| Mannkind Corporation | $54.38 | 2021-2024 | |
| Valeritas, INC. | $52.35 | 2019 | |
| Corcept Therapeutics | $45.17 | 2025 | Korlym |
| Amneal Pharmaceuticals LLC | $33.93 | 2024-2025 | Unithroid |
| Currax Pharmaceuticals LLC | $32.65 | 2025 | Contrave |
| Vivus LLC | $30.58 | 2019-2022 | |
| Lifescan, INC. | $30.00 | 2019-2020 | |
| Pfizer INC. | $21.41 | 2024 | |
| Insulet Corporation | $20.01 | 2024 | Omnipod |
| Pharmacosmos Therapeutics INC. | $18.98 | 2025 | Monoferric |
| Neurocrine Biosciences, INC. | $18.36 | 2024 | |
| Embecta Corp. | $17.84 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Radius Health, INC. | $16.63 | 2019 | |
| Acella Pharmaceuticals, LLC | $15.40 | 2024 | NP Thyroid 60 |
| Esperion Therapeutics, INC. | $14.98 | 2021 | |
| Clarus Therapeutics INC. | $14.87 | 2021 | |
| Eisai INC. | $14.66 | 2019 | |
| Sanofi Pasteur INC. | $13.64 | 2019 | |
| Azurity Pharmaceuticals, INC. | $13.61 | 2023 | Adthyza |
| Becton, Dickinson and Company | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Torrens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.